Bloomage Biotechnology Corp Ltd
SSE:688363
Intrinsic Value
Bloomage Biotechnology Corp. Ltd. engages in the production of hyaluronic acid, sodium hyaluronate bulk drugs, and medical supplements through fermentation. [ Read More ]
The intrinsic value of one
Bloomage Biotechnology Corp Ltd
stock under the Base Case scenario is
79.12
CNY.
Compared to the current market price of 58.93 CNY,
Bloomage Biotechnology Corp Ltd
is
Undervalued by 26%.
Bloomage Biotechnology Corp Ltd's market capitalization is 28.4B CNY.
Bloomage Biotechnology Corp Ltd stock price is 58.93 CNY.
Bloomage Biotechnology Corp Ltd stock price (58.93 CNY) is 26% less than its Intrinsic Value (79.12 CNY).
Bloomage Biotechnology Corp Ltd stock (43.56 CNY) is 26% less than its price (58.93 CNY). Open DCF Valuation
Bloomage Biotechnology Corp Ltd stock price (58.93 CNY) is 49% less than its Relative Value (114.67 CNY). Open Relative Valuation
Bloomage Biotechnology Corp Ltd has upside potential of 64% compared to the average analyst price target.
Open Wall St Estimates
Bloomage Biotechnology Corp Ltd's Revenue has grown by 0% over the past 12 months.
Bloomage Biotechnology Corp Ltd has negative Free Cash Flow for the last twelve months.
Bloomage Biotechnology Corp Ltd's ROE (Return on Equity) for the past 12 months is positive and is equal to 12%.
Bloomage Biotechnology Corp Ltd's ROE (Return on Equity) has decreased in the last 3 years from 14% to 12%.
Bloomage Biotechnology Corp Ltd's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 13%.
Bloomage Biotechnology Corp Ltd's ROIC (Return on Invested Capital) has decreased in the last 3 years from 20% to 13%.
Bloomage Biotechnology Corp Ltd has positive Net Income for the last twelve months.
Bloomage Biotechnology Corp Ltd's Revenue is forecast to grow at a rate of 12% per year over the next 3 years.
Bloomage Biotechnology Corp Ltd has positive three-year average ROE (Return on Equity): 15%. The company is efficient at transforming stockholders' equity into net income.
Bloomage Biotechnology Corp Ltd has positive Operating Income for the last twelve months.
Bloomage Biotechnology Corp Ltd has positive three-year average ROIC (Return on Invested Capital): 18%. The company is efficient at using invested capital to generate operating income.
Bloomage Biotechnology Corp Ltd's Revenue has been growing by an exceptional 42% per year for the last 3 years.
Bloomage Biotechnology Corp Ltd has positive Gross Profit for the last twelve months.
Bloomage Biotechnology Corp Ltd's short-term assets (3B CNY) exceed its short-term liabilties (1B CNY).
Bloomage Biotechnology Corp Ltd's D/E (Debt to Equity) is very low and is equal to 0.01.
Bloomage Biotechnology Corp Ltd's long-term assets (8B CNY) exceed its long-term liabilties (2B CNY).
Bloomage Biotechnology Corp Ltd has negative Net Debt. This means that the company has more cash and short-term investments (964m CNY) than debt (84m CNY).
Bloomage Biotechnology Corp Ltd's Altman Z-Score is very high and is equal to 18.27.
Valuation Backtest
Bloomage Biotechnology Corp Ltd
Run backtest to discover the historical profit from buying and selling
Bloomage Biotechnology Corp Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Bloomage Biotechnology Corp Ltd
Balance Sheet Decomposition
Bloomage Biotechnology Corp Ltd
| Current Assets | 3.3B |
| Cash & Short-Term Investments | 964.1m |
| Receivables | 611.6m |
| Other Current Assets | 1.7B |
| Non-Current Assets | 5.1B |
| Long-Term Investments | 597.9m |
| PP&E | 3.2B |
| Intangibles | 739.1m |
| Other Non-Current Assets | 523.1m |
| Current Liabilities | 1.2B |
| Accounts Payable | 621m |
| Accrued Liabilities | 209.8m |
| Short-Term Debt | 35m |
| Other Current Liabilities | 349.8m |
| Non-Current Liabilities | 296.5m |
| Long-Term Debt | 49.3m |
| Other Non-Current Liabilities | 247.1m |
Earnings Waterfall
Bloomage Biotechnology Corp Ltd
|
Revenue
|
6.3B
CNY
|
|
Cost of Revenue
|
-1.7B
CNY
|
|
Gross Profit
|
4.6B
CNY
|
|
Operating Expenses
|
-3.7B
CNY
|
|
Operating Income
|
893.2m
CNY
|
|
Other Expenses
|
-85.3m
CNY
|
|
Net Income
|
807.9m
CNY
|
Free Cash Flow Analysis
Bloomage Biotechnology Corp Ltd
Profitability Score
Profitability Due Diligence
Bloomage Biotechnology Corp Ltd's profitability score is 61/100. The higher the profitability score, the more profitable the company is.
Score
Bloomage Biotechnology Corp Ltd's profitability score is 61/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Bloomage Biotechnology Corp Ltd's solvency score is 84/100. The higher the solvency score, the more solvent the company is.
Score
Bloomage Biotechnology Corp Ltd's solvency score is 84/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Bloomage Biotechnology Corp Ltd
According to Wall Street analysts, the average 1-year price target for
Bloomage Biotechnology Corp Ltd
is 96.54 CNY
with a low forecast of 55.55 CNY and a high forecast of 144.6 CNY.
Shareholder Return
Price
Bloomage Biotechnology Corp Ltd
| Average Annual Return | 16.36% |
| Standard Deviation of Annual Returns | 42.47% |
| Max Drawdown | -83% |
| Market Capitalization | 28.4B CNY |
| Shares Outstanding | 481 678 242 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Bloomage Biotechnology Corp Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Bloomage Biotechnology Corp. Ltd. engages in the production of hyaluronic acid, sodium hyaluronate bulk drugs, and medical supplements through fermentation. The company is headquartered in Jinan, Shandong and currently employs 3,214 full-time employees. The company went IPO on 2019-11-06. The firm's products include raw material products, medical end products, functional skin care products and functional foods. The raw material products include a series of bioactive products with hyaluronic acid as the core, which are widely used in the fields of drugs, medical devices, cosmetics, functional food and general food. The medical end products are divided into medical beauty and medicine, including ophthalmic viscoelastics, medical lubricants, soft tissue fillers, medical skin protectors and others. The functional skin care products include lotion, cream, facial mask, hand mask and others. The functional foods include hyaluronic acid water, hyaluronic acid food and others.
Contact
IPO
Employees
Officers
The intrinsic value of one
Bloomage Biotechnology Corp Ltd
stock under the Base Case scenario is
79.12
CNY.
Compared to the current market price of 58.93 CNY,
Bloomage Biotechnology Corp Ltd
is
Undervalued by 26%.
You don't have any saved screeners yet
